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Abstract
We investigated the transcriptional pathways activated by estrogen receptor-a and their relationship with
patient survival after treatment with endocrine therapy. From this analysis, we propose that multimodal
assessment of breast tumors, using a combination of estrogen receptor-a status, estrogen receptor-a mRNA
expression, and genomic indicators of estrogen pathway activity, could be useful for both research and
treatment stratiﬁcation.
Background: Molecular markers have transformed our understanding of the heterogeneity of breast cancer and have
allowed the identiﬁcation of genomic proﬁles of estrogen receptor (ER)-a signaling. However, our understanding of the
transcriptional proﬁles of ER signaling remains inadequate. Therefore, we sought to identify the genomic indicators of
ER pathway activity that could supplement traditional immunohistochemical (IHC) assessments of ER status to better
understand ER signaling in the breast tumors of individual patients.Materials and Methods:We reduced ESR1 (gene
encoding the ER-a protein) mRNA levels using small interfering RNA in ERþMCF7 breast cancer cells and assayed for
transcriptional changes using Affymetrix HG U133 Plus 2.0 arrays. We also compared 1034 ERþ and ER breast
tumors from publicly available microarray data. The principal components of ER activity generated from these ana-
lyses and from other published estrogen signatures were compared with ESR1 expression, ER-a IHC, and patient
survival. Results: Genes differentially expressed in both analyses were associated with ER-a IHC and ESR1 mRNA
expression. They were also signiﬁcantly enriched for estrogen-driven molecular pathways associated with ESR1,
cyclin D1 (CCND1), MYC (v-myc avian myelocytomatosis viral oncogene homolog), and NFKB (nuclear factor
kappa B). Despite their differing constituent genes, the principal components generated from these new analyses and
from previously published ER-associated gene lists were all associated with each other and with the survival of patients
with breast cancer treated with endocrine therapies. Conclusion: A biomarker of ER-a pathway activity, generated using
ESR1-responsive mRNAs in MCF7 cells, when used alongside ER-a IHC and ESR1 mRNA expression, could provide a
method for further stratiﬁcation of patients and add insight into ER pathway activity in these patients.
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Multimodal Assessment of ER mRNA ProﬁlesIntroduction of cancer.25-28 In breast cancer, integrated studies have now
Breast cancer is the most common cancer among women and the
leading cause of cancer death in women worldwide. It is a multi-
factorial disease, with considerable interpatient heterogeneity and
complex etiology involving different genetic, endocrinologic, envi-
ronmental, and lifestyle inﬂuences.1 The hormone estrogen plays a
pivotal role in the pathogenesis of breast cancer,2 and the deter-
mination of estrogen receptor-a (ER-a) status of a breast tumor
using immunohistochemistry (IHC) is a longstanding molecular
diagnostic test used to stratify breast cancer patients for endocrine-
based treatment. The identiﬁcation of ER-a in breast tumors using
IHC predicts an increased likelihood of a response to endocrine-
based therapy. Endocrine therapy is given to > 95% of patients
with ERþ tumors; however, a proportion of these patients will not
have a treatment response or the cancer will become resistant to
tamoxifen or other endocrine therapies over time.3
Although ER IHC is the current standard of care to determine
ER status, concerns have been raised regarding inconsistencies in
assigning ER status using IHC. It has been estimated that  20% of
IHC assessments of ER status might be inaccurate (false-positive or
false-negative result) because of a number of factors such as varia-
tions caused by IHC analysis, including tissue handling, IHC ﬁx-
ation methods, antigen retrieval techniques, antibodies used and
their afﬁnity and speciﬁcity, scoring practices, positivity cutoff
thresholds, and interpretation criteria4,5 (also described in 4 re-
views6-9). It is also possible that some ER tumors might express
functional variant ER-a protein isoforms that are not detected
during IHC.10,11
Hence, international guidelines were established by the American
Society of Clinical Oncology/College of American Pathologists to
standardize the laboratory protocols for ER, progesterone receptor
(PGR), and Erb-b2 receptor tyrosine kinase 2/HER2 (ERBB2)
testing in breast cancer. The threshold for ER staining positive and
the determination of ER status was set at 1% positive stain-
ing,4,9,12,13 because it has been shown that patients with tumors
with as little as 1% ER positivity will beneﬁt from endocrine
therapy.4,14,15 Despite these useful guidelines, room still exists for
variability in the determination of ER/PGR status of tumors. For
example, the guidelines recommend the use of a number of anti-
bodies such as the commonly used 1D5, 6F11, and the more
sensitive SP1 for ER, and 3 different antibodies for PGR.16
Furthermore, tumors can be scored using multiple methods,
including the H-score, Allred score, and a quick score.16 Although
IHC is currently the reference standard method used to ascertain
ER status in breast cancer, IHC provides no assessment of whether
the estrogen signaling pathway targeted by endocrine therapy is
actually functional in individual tumors. Therefore, a number of
studies are now attempting to address this issue using gene
expression proﬁling to more accurately deﬁne ER status.14,17-22
Gene expression proﬁling research using primary breast tu-
mors23,24 has transformed our understanding of the molecular
heterogeneity of breast cancer. Many genomic studies now inte-
grate analysis of primary cancers using various genomic, tran-
scriptomic, proteomic, and clinical parameters, such as exome and
microRNA sequencing, tumor mutational data, DNA copy num-
ber and methylation, mRNA expression and protein expression
arrays, and in vitro experimental data, to investigate various aspectsnical Breast Cancer Month 2016enabled, for example, the classiﬁcation of breast cancer using RNA
and DNA proﬁling,29 the investigation of pathway signaling in
breast cancer,30 the association of DNA number variations with
gene expression and patient survival,31 and the investigation of
in vivo biology from in vitro experiments.32,33 Genomic proﬁling
studies have also facilitated breast cancer prognostication and
stratiﬁed therapy,24,34 including ﬁrst-generation signatures, such as
MammaPrint (Agendia BV, Amsterdam, Netherlands), Oncotype
DX (Genomic Health, Inc, Redwood City, CA), and the Genomic
Grade Index (MapQuant Dx, Ipsogen, France) to the more recent
Prosigna Assay based on the PAM50 test (NanoString Technolo-
gies, Inc, Seattle, WA), Breast Cancer Index (BioTheranostics, San
Diego, CA), and Endopredict (Sividon Diagnostics GmbH, Koln,
Germany). However, evidence is still being gathered regarding the
clinical utility of breast cancer genomic assays35-38; therefore,
traditional nongenomic pathology examination remains a key
component of the standard of care.
In general, good concordance has been reported between the ER
status determined by IHC and the ER status ascertained using
MapQuant,39 TargetPrint,40 and 3 molecular assays, BluePrint,
MammaPrint, and TargetPrint.41 Allott et al42 also found high
concordance for ER status of >10% positivity between IHC and
RNA-based intrinsic subtypes.42 However, in these studies, the
concordance rates for PGR status were always lower than those for
ER status. Possible implications exist when deciding on the treat-
ment options for patients when the hormone receptor status
determined using IHC or molecular tests are not in accordance.
Thus, the use of microarray data to assign ER/PGR status still needs
to be reﬁned.
ESR1 (the ESR1 gene encodes the ER-a protein) mRNA
expression drives global patterns of gene expression in breast cancer
cells.43 Despite years of investigation, our understanding of the ER
signaling pathways that mediate these gene expression programs is
still incomplete. Breast tumors are usually designated as either ERþ
or ER according to the percentage of cells with detectable ER-a
staining (and, indirectly, the intensity of the staining within the
positive cells). In contrast, ESR1 mRNA expression is a continuous
variable when measured using microarray or reverse transcription-
quantitative polymerase chain reaction (RT-qPCR) and exhibits a
wide range of values.18,19,44 This range of ESR1 mRNA expression
could likely translate into a range of ER transcriptional activity in a
breast tumor and might, along with intratumor ER pathway het-
erogeneity, inﬂuence a patient’s response to endocrine therapy.45
For example, low expression of ESR1 mRNA in ERþ breast can-
cer has been associated with tamoxifen resistance,46 with high levels
of ESR1 mRNA expression identiﬁed by in situ hybridization
associated with tamoxifen responsiveness.21 The activity of tran-
scription factors such as the ER can be inferred by measuring the
expression levels of sets of their transcriptional target genes,47 which
are often statistically summarized into a single value reﬂecting
transcription factor activity, such as a “principal component”
(PC).48 The concept of using statistical summaries of the expression
of gene sets, including PC analysis, to estimate the activity of spe-
ciﬁc molecular pathways has been widely used to study breast
cancer, such as triple-negative breast cancer.49 This type of analysis
is also useful when attempting to integrate data from multiple
Anita Muthukaruppan et alsources, such as DNA methylation and gene expression data50 or
studying the relationship between single nucleotide polymorphisms
and trastuzumab resistance in breast cancer cell lines.51 Several gene
sets associated with ER signaling have been identiﬁed for use in
analysis. These include gene sets that can differentiate between ERþ
and ER tumors,52 estrogen-regulated genes that predict survival
or recurrence of patients with ERþ cancer treated with tamox-
ifen,46,53-56 and the estrogen receptor attractor metagenes from the
2012 DREAM (Dialogue for Reverse Engineering Assessments and
Methods) Breast Cancer Prognosis Challenge.57
It is becoming evident that the assessment and determination of
ESR1 mRNA expression levels in a tumor are also important, in
addition to the IHC-determined ER status (based on ER-a protein
expression). Moreover, an assessment of an intact estrogen signaling
pathway is imperative to predict a patient’s response to endocrine
therapy. Despite numerous studies of ER-a signaling in breast
cancer, the relationship between ER-aedriven transcriptional pro-
grams and its relationship with ER status and ESR1 mRNA tran-
script abundance and its distribution across a full range of breast
tumors remains unclear.
Therefore, in the present study, we initially performed experi-
ments to identify ER-aedependent gene expression patterns in a
simple and well-controlled cell culture model. Speciﬁcally, we
mapped the gene expression changes after small interfering RNA
(siRNA)-mediated reduction of ESR1 levels in ERþ MCF7 breast
cancer cells. Next, the expression of this gene set and 12 previously
published ER-associated gene sets were interpreted in the context of
1034 patients with breast cancer. The distribution of these gene
sets, ESR1 mRNA expression, and ER status (from IHC) were
interpreted with other clinicopathologic data across breast tumor
subtypes. From our analysis, we suggest that genomic indicators that
summarize estrogen pathway activity from gene expression data,
when used with IHC-determined ER status and ESR1 mRNA
expression, can provide a useful proﬁle of ER signaling in the breast
tumors of individual patients.
Materials and Methods
Cell Culture and Transfection of MCF7 Cells With
siRNAs
MCF7 breast cancer cells were purchased from the American
Type Culture Collection (Manassas, VA) and cultured in Dulbec-
co’s modiﬁed Eagle medium (Thermo Fisher Scientiﬁc Inc, Wal-
tham, MA), 10% vol/vol fetal bovine serum (Thermo Fisher
Scientiﬁc Inc), 0.01 mg/mL bovine insulin (Sigma-Aldrich, St
Louis, MO), 2 mM L-glutamine (Thermo Fisher Scientiﬁc Inc),
1 mM sodium pyruvate (Thermo Fisher Scientiﬁc Inc), 1 U/mL
penicillin G (Thermo Fisher Scientiﬁc Inc), and 1 mg/mL strepto-
mycin sulfate (Thermo Fisher Scientiﬁc Inc) in humidiﬁed air with
5% vol/vol carbon dioxide at 37C.
A new batch of MCF7 cells was obtained from the American
Type Culture Collection for the present study and used within 10
passages of purchase. Stealth-modiﬁed siRNA duplex HSS176619
(Thermo Fisher Scientiﬁc Inc) was used to target ESR1; BLOCK-iT
Fluorescent Oligo (Thermo Fisher Scientiﬁc Inc) and Stealth RNAi
Negative Control Medium GC Duplexes (Thermo Fisher Scientiﬁc
Inc) were used as positive and negative nontargeting transfection
controls, respectively. Transfections were performed in triplicateusing a “reverse transfection”method. A transfection mix containing
2.5 mL of RNAiMAX transfection reagent (Thermo Fisher Scientiﬁc
Inc) and 5 nM siRNA in 500 mL of OptiMEM serum-free media
(Thermo Fisher Scientiﬁc Inc) was incubated for 20 minutes at
room temperature and added dropwise to 5.0  105 cells in 2.5 mL
of antibiotic-free, complete growth media per well in a 6-well plate.
The cells were incubated at 37C for 24 hours, the media removed,
and the cells harvested using 1 mL of TRIzol reagent (Thermo
Fisher Scientiﬁc Inc). The details of the optimization procedure are
provided in the Supplemental Methods (available in the online
version).
RNA Extraction and Microarray Analysis of MCF7 Cells
Total RNA from MCF7 cells was isolated from TRIzol ho-
mogenates using chloroform and puriﬁed using the PureLink RNA
mini kit according to the manufacturer’s protocol (Thermo Fisher
Scientiﬁc Inc). RNA yields and purity were determined using the
NanoDrop spectrophotometer (NanoDrop Technologies Inc, Wil-
mington, DE), and RNA integrity was assessed using the Experion
Automated Electrophoresis System according to the manufacturer’s
protocol (Bio-Rad Laboratories, Berkeley, CA). The average 260/
280 purity ratio was 2.0 (range, 1.9-2.0), and the RNA quality
indicator was 9.7 (range, 9.5-9.8). Total RNA (1 mg) was labeled,
fragmented, and hybridized to Affymetrix Human Genome U133
Plus 2.0 arrays in accordance with the manufacturer’s protocol
(Affymetrix, Santa Clara, CA). Raw and normalized microarray data
are available in the Gene Expression Omnibus (GEO) record
GSE37820. Quality control was performed using Expression
Console (Affymetrix) and dChip before quantile normalization us-
ing R statistical software (available at: http://cran.r-project.org/) and
the robust multichip averaging (RMA) algorithm with background
correction and loess splining, as implemented in the R “affy”
package. The extent of ESR1 mRNA knockdown identiﬁed
using microarrays was conﬁrmed using RT-qPCR (see
Supplemental Methods available in the online version).
Bioinformatic Analyses of Microarray and RNA
Sequencing Data
Microarray data for 1034 primary breast tumors were assembled
from raw Affymetrix Human Genome U133 “.cel” ﬁles, available on
GEO: GSE1456, GSE3494, GSE4922, GSE6532, GSE7390,
GSE36771, GSE36772, and GSE36773. A total of 22,277 probe
sets common to both the U133 Plus 2.0 and the U133A version 2
arrays were used for the present analysis, as described previously.58
Array quality assessment was performed using the “AffyQCReport”
package in R and normalized using RMA. Normalized gene level
RNA sequencing (RNAseq) and clinical data from 1023 breast tu-
mors were downloaded from the Cancer Genome Atlas data portal
(available at: https://tcga-data.nci.nih.gov/tcga/) and processed using
the “rsem” method in R. Probe sets differentially expressed between
experimental samples were ranked using the linear models for
microarray data (LIMMA) package in R. The lists of differentially
expressed probe sets were tested for enrichment of particular func-
tional categories using ingenuity pathways analysis (Ingenuity Sys-
tems; available at: http://www.ingenuity.com). The ESR1 probe set
205225_at was used as the indicator of ESR1 expression in all
analyses of microarray data (see Supplemental Methods available inClinical Breast Cancer Month 2016 - 3
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was calculated from the log2 expression data by determining the
relative expression level of ESR1 probe set 205225_at, ranked against
all other probe sets on the array.
Gene expression data from ESR1 siRNA-treated MCF7 cells
were used to develop a putative biomarker of estrogen activity in
clinical samples. The genes signiﬁcantly regulated in MCF7 cells by
ESR1 siRNA treatment were identiﬁed. Subsequently, the data
corresponding to these genes were extracted from clinical samples
and a PC was inferred from these data. The PC analysis was per-
formed by singular value decomposition using the “svd” function in
R, after the data had been zero centered and scaled to unit variance.
Because the signs of PCs can be inconsistent, in all cases, PC signs
were set such that the PC correlation with ESR1 expression was >
0. Statistical meta-analysis was performed using the “metaMA”
package in R. Molecular subtypes were assigned to each tumor using
the single sample predictor algorithm applied per cohort.59 Spear-
man’s correlation coefﬁcients between any 2 probe sets were
calculated using the “cor” function in R. The intersection of genes
between selected numbers of gene sets were plotted using our own
modiﬁcations of the “heatmap.2” function of the “gplots” package
in R. Kaplan-Meier survival analysis with log-rank tests and Cox
proportional hazards analysis was performed using the “survival”
package in R (see Supplemental Methods for a detailed description
available in the online version). The visualizations for many of the
analyses presented in the present report were scripted using the R
“shiny” package from the R studio framework (available at: http://
www.rstudio.com/products/shiny/shiny-server/).
Results
Effect of ESR1 siRNA Treatment on ESR1 Expression in
MCF7 Cells
To identify the gene expression patterns driven by ER-a in a
controlled in vitro system, we treated cultures of MCF7 cells with
an siRNA to ESR1. The average knockdown of ESR1 was 72.5%
and 78.6% as assessed by microarray analysis (Figure 1A) and RT-
qPCR (Figure 1B), respectively. Before and after ESR1 mRNA
knockdown in MCF7 cells, the mean percentile ranks (see Materials
and Methods) of ESR1 expression on the microarrays were 93%
and 76%, respectively. These percentile ranks were then mapped to
the expression percentile ranks of the same Affymetrix ESR1 probe
set 205225_at in 1034 breast tumors, separated into ER and ERþ
(Figure 1C). Before ESR1 knockdown, ESR1 expression in MCF7
cells was at a level typical of most ERþ luminal tumors. However,
when the analysis was restricted to only luminal A tumors
(Figure 1D), it was evident that after siRNA treatment, ESR1
expression was reduced to a level less than that of any ERþ luminal
A tumors. This suggests that ESR1 siRNA treatment of MCF7 cells
allows a comparison between cells with ESR1 levels typical of most
ERþ luminal A tumors and cells with ESR1 levels less than those
found in any ERþ luminal A tumor.
Genes Showing Altered Expression After ESR1 siRNA
Treatment of MCF7 Cells
The experimental objective was to identify differential mRNA
expression between MCF7 cells in which ER-aedriven gene
expression responses were high versus low. Therefore, to allownical Breast Cancer Month 2016ER-aemediated gene expression programs to be driven by steroid
hormone components of culture media and by the endogenous
estrogens produced by the cells, we followed a procedure similar to
that used by others,60,61 in which no steroid hormone depletion
steps were performed (ie, serum was not charcoal stripped and
phenol red was not removed from the media), and no exogenous
estrogen was added to the media. Analysis of the gene expression
data in MCF7 cells after ESR1 knockdown using LIMMA identi-
ﬁed 50 Affymetrix probe sets that were differentially expressed
(multiple testing-adjusted threshold set at P  .001; Supplemental
Table 1; available in the online version). These mRNAs consisted of
39 unique annotated genes (some could not be annotated or were
duplicate probe sets) that included ESR1 targets such as the PGR
anterior gradient 2 homolog (AGR2), carbonic anhydrase XII
(CA12) and MYC (v-myc avian myelocytomatosis viral oncogene
homolog). These genes are referred to as the MCF7-ESR1-siRNA
gene set. This gene set appears to constitute several interconnected
molecular pathways involving ESR1, CCND1 (cyclin D1), MYC,
and NFKB (nuclear factor kappa B). The multiple testing-adjusted
enrichment threshold was set at P  .05. The genes constituting
these canonical pathways are listed in Supplemental Table 2
(available in the online version).
Generation of PC of ER-a Pathway Activity From the
MCF7-ESR1-siRNA Gene Set
The expression of genes constituting the MCF7-ESR1-siRNA
gene set was examined in microarray data from 1034 breast tumors
assembled from several published cohorts (see Materials and
Methods). The expression values of 28 of the 39 members of this
gene set, for which data could be generated across all 1034 breast
tumors, are shown as a heatmap in Figure 2. A ﬁrst PC (excluding
ESR1 and including PGR; see Materials and Methods) was gener-
ated to provide a statistical summary of these mRNAs for each
tumor and was used to sort the tumors across the heatmap in
Figure 2. We hypothesized that this PC of the MCF7-ESR1-siRNA
gene set might provide a robust indicator or biomarker of ER-a
transcriptional activity in breast tumors. Sorting tumors according
to the magnitude of this ﬁrst PC also appeared to segregate the
tumors, in general, by molecular subtype, grade, and ER status
(Figure 2). Tumors in the lowest 25% of PC magnitude were
mostly grade 2 or 3 tumors and of the basal-like or ERBB2 sub-
types, with 87% being ER by IHC. In contrast, the tumors in the
highest 75% of PC magnitude were mostly luminal A, luminal B, or
normal-like subtypes, with 95% ERþ.
We also noted that although most ERþ tumors had greater ESR1
mRNA expression levels than ER tumors, the ESR1 mRNA
expression range of ERþ and ER tumors overlapped considerably
(ESR1 microarray probe set 205225_at; Supplemental Figure 1;
available in the online version). Similarly, an ESR1 mRNA
expression overlap was present among the breast cancer molecular
subtypes, with the distributions most similar between luminal A and
luminal B tumors (Supplemental Figure 2; available in the online
version).
The MCF7-ESR1-siRNA ﬁrst PC for 5 of the individual
microarray study cohorts (Figure 3A-E) and as a combined data set
of all 5 cohorts (n ¼ 1034; Figure 3F) correlated with ESR1 mRNA
abundance. In addition to consistency across independent
Figure 1 Assessment of ESR1 (Gene Encoding Estrogen Receptor [ER]-a Protein) mRNA Expression After Small Interfering RNA
(siRNA) Knockdown in MCF7 Cells. (A) Log2 Expression Levels of ESR1 mRNA Measured by Microarray From Hybridization to
Probe Set 205225_at. Each Biologic Sample Was Assayed in Triplicate. (B) Normalized Measurement of ESR1 mRNA Levels in
Untransfected, Control siRNA- or ESR1 siRNA-Transfected MCF7 Cells Using Reverse Transcription Quantitative Polymerase
Chain Reaction. (C) Log2 ESR1 mRNA Expression Levels Shown as Percent Rank (Percentile of Expression) in MCF7 Cells
Transfected With siRNA Control (Circles) or ESR1 siRNA (Crosses) Were Plotted With All Breast Tumors (Sorted by Increasing
Percent Rank of ESR1 Expression) and Shown Separately as ERL and ERD Tumors (by Immunohistochemistry), and (D)
Luminal A Breast Tumors (Sorted by Increasing Percent Rank of ESR1 Expression)
Abbreviations: CON ¼ control; KD ¼ knockdown; UNT ¼ untreated.
Anita Muthukaruppan et almicroarray data sets, this relationship was also consistent across
analysis platforms (microarray vs. RNAseq). The MCF7-ESR1-
siRNA PC correlated with the ESR1 mRNA abundance from 1023
breast tumors from the Cancer Genome Atlas breast cancer RNAseq
data set (Supplemental Figure 3 in the online version). Both
Figure 3F and Supplemental Figure 3 (available in the online
version) revealed that a small proportion of patients assessed by IHC
to be ER actually had high ESR1 mRNA expression and high
activity of the ER pathway as inferred by PC analysis. In contrast, a
small proportion of patients determined to be ERþ by IHC
expressed low levels of ESR1 mRNA and low inferred activity of the
ER pathway. These 2 patient groups are potentially clinically rele-
vant (see Discussion). Analysis of the ESR1 mRNA abundance and
ER IHC status plotted with the MCF7-ESR1-siRNA PC distrib-
uted across the 5 breast cancer subtypes in the 1034 breast tumors
showed that the ESR1 mRNA expression and the MCF7-ESR1-
siRNA PC progressively increased from basal-like, ERBB2, andnormal-like to luminal tumors (Figure 4). The MCF7-ESR1-siRNA
PC also correlated well with ESR1 mRNA and IHC PGR status
(Figure 5A) and PGR mRNA and IHC PGR status (Figure 5B)
across all breast tumors. A wide range of ER pathway activity was
found in IHC PGR tumors that also had very low PGR mRNA
expression (Figure 5B).
Comparison of Genes Differentially Expressed After ESR1
Knockdown and Other Estrogen Pathway-Associated Gene
Sets With Patient Survival
We then identiﬁed 23 Affymetrix probe sets, each corre-
sponding to a unique gene, that were differentially expressed
between ERþ and ER tumors from the collated breast cancer
cohort (multiple testing corrected, P ¼ .001; genes listed in
Supplemental Table 3; available in the online version). We
assessed the intersection between this gene set with the MCF7-
ESR1 gene set and 12 other previously published gene setsClinical Breast Cancer Month 2016 - 5
Figure 2 Heatmap Depicting mRNA Expression of Probe Sets of MCF7-ESR1 (Gene Encoding Estrogen Receptor [ER]-a Protein)-siRNA
(Small Interfering RNA) Gene Set. Expression Values of 28 of 33 Members of MCF7-ESR1-siRNA Gene Set for Which Data
Could Be Generated Across All 1034 Breast Tumors Were Used to Generate a Principal Component (PC). Where Multiple
Probe Sets Were Available for Any 1 Gene, These Were Averaged. Tumors (n [ 1034) Were Arranged From Low PC
Magnitude (Green) to High PC Magnitude (Red; Left to Right). Genes Used to Infer the PC of ER Signaling Were Hierarchically
Clustered Using Euclidean Distance and Ward’s Method Linkage (Dendrogram Left of Heatmap). Their mRNA Expression
Levels Across the Breast Tumors Are Indicated in the Heatmap (High, Red; Low, Green). The Centroid Refers to the Mean
Expression Within Each Tumor
Abbreviations: ERBB2 ¼ Erb-b2 receptor tyrosine kinase 2/HER2; IHC ¼ immunohistochemistry.
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cancer (gene lists provided in Supplemental Table 3; available in
the online version). The intersection of genes between gene sets
that represented the estrogen response and purportedly related to
estrogen function in breast cancer revealed little overlap with each
other (Supplemental Figure 4; available in the online version).
For example, the set of 39 genes differentially expressed after
ESR1 knockdown in MCF7 cells and the set of 34 genes differ-
entially expressed between ERþ and ER tumors had only 1 gene
in common, PGR.
To assess which aspects of ER biology are most highly associated
with patient prognosis, we analyzed the distant metastasis-free sur-
vival (DMFS) of ERþ patients from the 1034 breast cancer cohort,
using the gene sets listed in Supplemental Table 3 (available in the
online version). Analyses of 326 breast cancer patients who un-
derwent endocrine therapy but not chemotherapy showed that the
MCF7-ESR1-siRNA PC was weakly to moderately associated with
DMFS in these patients (Cox proportional hazards, P ¼ .0001);
however, the association between the MCF7-ESR1-siRNA PC and
DMFS was not statistically signiﬁcant in untreated patientsnical Breast Cancer Month 2016(Figure 6). Similarly, the PC of genes identiﬁed to be differentially
expressed between ER and ERþ tumors and PCs of the Endo-
predict,55 PAM50,62 and simpliﬁed tamoxifen predictor56 gene sets
were signiﬁcantly associated with DMFS in endocrine therapy-
treated patients but had a weaker association with DMFS in un-
treated patients (Figure 6; Supplemental Table 4; available in the
online version). The ESR1 mRNA level itself and the PCs of the
additional ER-associated gene sets showed a range of association
with patient prognosis, in some cases showing a trend toward a
stronger association after endocrine treatment than in untreated
patients (Supplemental Table 4; available in the online version).
In the 1034 breast tumor data set, a group of ER IHC patients
who had not received endocrine therapy nevertheless had high
ESR1 mRNA expression and high inferred ER pathway activity
(Figure 7A). Given their apparent ER pathway activation, it is
possible that a subset of these patients might, in fact, have beneﬁted
from endocrine therapy. In contrast, a group of ERþ patients who
had received endocrine therapy had low ESR1 mRNA expression
and low inferred ER pathway activity, possibly representing het-
erogeneous tumors with focal ER activation (Figure 7B).
Figure 3 Comparison of ESR1 (Gene Encoding Estrogen Receptor [ER]-a Protein) mRNA Expression, MCF7-ESR1-siRNA (Small
Interfering RNA) First Principal Component (PC) and ER Status. Log2 ESR1 mRNA Levels Were Plotted Against MCF7-ESR1-
siRNA PC in Breast Tumors From 5 Selected Microarray Data Sets. (A) GSE36771 (n [ 107), (B) GSE1456 (n [ 159), (C)
GSE3494 (n[ 232), (D) GSE6532 (n[ 241), (E) GSE36772 (n[ 100), (F) All 5 Data Sets (n[ 1034). ER Status Determined
by Immunohistochemistry Shown as Red for ERL Tumors and Blue for ERD Tumors
Anita Muthukaruppan et alWe then assessed whether these ER-associated gene sets might be
able to provide additional prognostic or predictive information to
ER IHC status or ESR1 mRNA information for breast cancer pa-
tients who had received endocrine therapy but not chemotherapy
(see Supplemental Methods in the online version). The addition of
ﬁrst PCs from the following gene sets, to either ER IHC status or
ESR1 mRNA levels, generated logistic regression models that might
be superior to those based on either ER IHC status or ESR1 mRNA
levels alone: MCF7-ESR1-siRNA ﬁrst PC; the simpliﬁed tamoxifen
predictor; or Endopredict (Supplemental Table 5; available in the
online version). The addition of the ﬁrst PC of all 3 of these gene
sets increased the separation of the hazard ratio’s 95% conﬁdence
intervals away from 1.0, reduced the model Akaike information
criterion, and increased model C indexes for endocrine-treated pa-
tients. However, the effect of adding these gene set PCs to models
based on ER IHC status or to ESR1 mRNA information for un-
treated patients was inconsistent, as was the effect of adding other
ER-associated gene sets to ER status or ESR1 mRNA information
for either endocrine-treated patients or untreated patients
(Supplemental Table 5; available in the online version).Discussion
ER-aeRegulated Molecular Pathways in MCF7 Cells
One method of investigating the underlying biology in cancer cell
lines on a larger scale is to create as many different states of these cells
as possible using an experimental perturbation approach and then to
use computational methods, such as PC analyses or gene networks, to
model the gene expression data from these different cell states.63,64 By
treating the cell line as a system, the responses from the system such as
pathways and molecular interactions in cell perturbations such as the
overexpression of mutant genes, the knockdown of single or multiple
genes, or treatment with different hormones or chemotherapy drugs,
can be analyzed. MCF7 breast cancer cells have been extensively used
for in vitro perturbation experiments for extrapolation in vivo.63 Our
approach of knocking down target gene expression, in this case ESR1,
in the MCF7 cells was reciprocal to the approach used by Bild et al.65
They identiﬁed gene expression signatures that were associated with
the activation of oncogenic pathways using adenoviruses in quiescent
human mammary epithelial cells.65
In our study, we ﬁrst investigated mRNA expression changes
after siRNA knockdown of ESR1 in MCF7 cells using microarraysClinical Breast Cancer Month 2016 - 7
Figure 4 Comparison of ESR1 (Gene Encoding Estrogen Receptor [ER]-a Protein) mRNA Expression, MCF7-ESR1-siRNA (Small
Interfering RNA) Principal Component (PC) and ER Status Across Breast Cancer Subtypes. Log2 ESR1 mRNA Levels Were
Plotted Against MCF7-ESR1-siRNA PC in 1034 Breast Tumors Separated by Subtype. (A) Basal-Like (n [ 209), (B) Erb-b2
Receptor Tyrosine Kinase 2/HER2-Positive (n [ 100), (C) Normal-Like (n [ 176), (D) Luminal B (n [ 210), (E) Luminal A
(n [ 291; Tumors That Could Not Be Classiﬁed Into a Subtype Were Excluded). ER Status Determined by
Immunohistochemistry Shown as Red for ERL Tumors and Blue for ERD Tumors
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8 - Clito identify ESR1-regulated genes, including genes expressed because
of estrogen-independent ER signaling. Although recognizing that
MCF7 cells are derived from an advanced metastatic tumor, the
relatively high expression of ESR1 in MCF7 cells is in concordance
with our understanding that MCF7 cells more closely represent
luminal A breast tumors than other subtypes66,67 and with the
widespread use of MCF7 cells as a model of ERþ breast cancer. The
mRNAs that showed altered abundance between control samples
and ESR1 knockdown samples in MCF7 cells are components of
known estrogen-driven molecular pathways, including pathways
centered on CCND1, ESR1, MYC, and NFKB. These estrogen-
driven signaling pathways are known to be important for tumor
biology and are targets of endocrine therapy. For example, CCND1
has been shown to drive proliferation in breast cancer,68 MYCFigure 5 Comparison of ESR1 (Gene Encoding Estrogen Receptor [E
Component (PC) with ESR1 and Progesterone Receptor (PG
Were Plotted Against MCF7-ESR1-siRNA PC in 1034 Breas
Shown as Red for PGRL Tumors and Blue for PGRD Tumo
siRNA PC in 639 Breast Tumors (Remaining Tumors Had N
Immunohistochemistry Shown as Red for PGRL Tumors a
nical Breast Cancer Month 2016pathways are often activated in luminal B tumors,69 and NFKB
signaling is involved in resistance to endocrine-based therapy.70
Our MCF7 ESR1 siRNA experimental system does have limita-
tions. For example, it does not address signaling through the ER-b
receptor, which might allow responses to tamoxifen in ER pa-
tients.71 In addition, it does not address differential ER-a binding due
to redistribution of ER-a, FOXA1 (forkhead box A1),72 and other
cofactors such as the occurrences of ER-a and other splice variants.
The experimental system used in our analysis, like similar systems
used previously by others,60,61 contains no steroid hormone depletion
steps (the serum was not charcoal stripped and phenol red was not
removed from the media) and no addition of exogenous estrogens. In
this system, ER-aemediated gene expression programs are driven by
steroid hormone components of culturemedia and by the endogenousR]-a Protein) siRNA (Small Interfering RNA) First Principal
R) mRNA Expression and PGR Status. (A) Log2 ESR1 mRNA Levels
t Tumors. PGR Status Determined by Immunohistochemistry
rs. (B) Log2 PGR mRNA Levels Were Plotted Against MCF7-ESR1-
o PGR Status Available). PGR Status Determined by
nd Blue for PGRD Tumors
Figure 6 Association of Gene Sets With Distant Metastasis-Free Survival (DMFS) in Nonadjuvant Treated or Endocrine-Treated
Patients. Kaplan-Meier Survival Plots Showing Association of Principal Component of 4 Gene Sets: MCF7-ESR1 (Gene
Encoding Estrogen Receptor [ER]-a Protein)-siRNA (Small Interfering RNA), ERD Versus ERL, Endopredict, PAM50, and
Simpliﬁed Tamoxifen Predictor and Prognosis of Either Nonadjuvant-Treated or Endocrine-Treated Breast Cancer Patients.
Cox Proportional Hazards (CoxPH) and Log-Rank Test (LR) P Values Shown for 4 Gene Sets That Showed the Most Signiﬁcant
Association With DMFS in Patients Receiving Endocrine Therapy. High Indicates Greater Than the Quantile Cutoff; and Low,
Less Than the Quantile Cutoff
Anita Muthukaruppan et al
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Figure 7 Comparison of ESR1 (Gene Encoding Estrogen Receptor [ER]-a Protein) mRNA Expression, MCF7-ESR1-siRNA (Small
Interfering RNA) Principal Component (PC) and ER Status. Log2 ESR1 mRNA Levels Were Plotted Against MCF7-ESR1-siRNA
PC in Breast Tumors Separated by ER Status (Determined by Immunohistochemistry). (A) ERL Tumors (n [ 208) and (B)
ERD Tumors (n [ 822). Patients Who Received Endocrine Therapy Shown in Red and Patients Who Did Not Receive
Endocrine Therapy in Black
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10 -estrogens produced by the cells. Our PC of estrogen pathway activity
was also generated from 1 cell line, MCF7 breast cancer cells.
Although MCF7 cells have been used extensively as a model of ERþ
breast cancer and their molecular proﬁles closely resemble those of
luminal breast tumors, the estrogen signaling pathway in MCF7 cells
alone might not completely recapitulate estrogen signaling in het-
erogeneous breast tumors. However, that this approach was successful
for the purposes of the present study is supported by the observation
that known estrogen-dependent genes were induced or repressed after
siRNA reduction of ESR1 in this system.
ESR1 mRNA Has a Broad Range of Expression Levels in
Both ERþ and ER Breast Tumors
Our analyses showed that ESR1 mRNA is expressed over a range
of levels, and this expression overlaps between IHC-determined
ERþ and ER tumors, as described in other studies.18 Also, the
range of ESR1 mRNA expression might possibly translate into a
range of ER transcriptional activity in a breast tumor that could
inﬂuence the response to endocrine therapy.45 The MCF7-ESR1-
siRNA ﬁrst PC correlated with ESR1 mRNA expression levels and
was associated with the prognosis of patients treated with endocrine
therapies but not that of untreated patients. Luminal A and luminal
B tumors have a similar distribution of ESR1 mRNA expression and
inferred ER pathway activity according to our PC analysis. This
indicates that the different proliferative and clinical behavior of
these 2 subtypes is not simply due to differential expression of ESR1
mRNA or differential activity of the ER signaling pathway. Across
the other subtypes, a gradation of ESR1 mRNA expression and the
magnitude of the MCF7-ESR1-siRNA PC was seen. Compared
with ERþ tumors, most ER tumors have much lower ESR1
mRNA expression and reduced ER molecular pathway activity
inferred from the magnitude of the MCF7-ESR1-siRNA PC.
However, we observed 11 patients whose tumors expressed highClinical Breast Cancer Month 2016ESR1 mRNA levels (ESR1 probe set cutoff  10; see Materials and
Methods) and appeared to have a highly active ER pathway activity
(PC cutoff  0.01; see Materials and Methods) despite being
assigned ER status using IHC (Figure 3F, red dots).
Studies have supported the use of gene expression proﬁles to
determine ER status, either independently or in concert with ER
IHC.14,19,73 For instance, TargetPrint was developed by Agendia
and used to ascertain ESR1, PGR, and ERBB2 levels using gene
expression data. TargetPrint had high concordance with the ER and
PGR status determined by IHC and ERBB2 status determined by
ﬂuorescence in situ hybridization.74 Bastani et al17 used a 3-gene
classiﬁer (GATA3 [GATA binding protein 3], CA12, and a 701-
base pair-expressed sequence tag17) to determine ER status using
gene expression data. Neither ESR1 nor PGR mRNA expression
was used in their classiﬁer, and none of these genes, except for the
reference gene, b-actin, are contained in the Oncotype DX gene list.
However, the criteria for ER positivity in a breast tumor (>1%
stained nuclei) represents a local maximum. In contrast, RNA
analysis usually represents a global average of a tumor. Therefore,
the determination of ER status using gene expression data together
with IHC might have particular advantages, which has been pro-
posed by a number of groups,18,19,73 and seems likely to provide
useful additional information for treatment stratiﬁcation. For
example, it was shown that some ERþ patients with resistance to
tamoxifen treatment had low tumor ESR1 mRNA levels.46 Also,
Itoh et al75 suggested using ESR1 mRNA expression levels to
stratify patients with ER/PGRþ breast tumors for endocrine
therapy.
Identifying Gene Sets for Use With PC Analysis to Infer
ER Pathway Activity
ER-related gene sets have contributed to several prognostic and
predictive assays for breast cancer,46,53,57,76 including the Oncotype
Anita Muthukaruppan et alDX assay and the ECTO (European Cooperative Trial in Operable
Breast Cancer) clinical trial.77 The abundance of single RNA
transcripts such as CA12 , NPY1R (neuropeptide Y receptor Y1),
STC2 (stanniocalcin 2), DKC1 (dyskerin pseudouridine synthase),
or PGR might provide a more readily measurable marker of ER
transcriptional activity. However, improved technologies have
allowed the analysis of multiple RNAs downstream of a receptor of
biologic process to be analyzed accurately and inexpensively,
allowing statistical summaries of these RNAs (eg, by PC analysis) to
estimate the activity of speciﬁc molecular pathways. A key advantage
of using a large number of mRNA transcripts to generate a PC is its
inherent redundancy and hence robustness in that by having many
mRNAs account for a PC, the failure of  1 measurement can be
compensated for by other measured mRNA transcripts. Summari-
zing multiple tumor RNAs into a single biomarker is increasingly
common. For example, a recent study used gene set enrichment
analysis to infer the activity of immune gene sets in published breast
cancer microarray cohorts.78
Our data suggest that the sets of mRNAs differentially expressed
in MCF7 cells after siRNA targeting of ESR1, or differentially
expressed between tumors identiﬁed as ERþ and ER by IHC, are
additional candidate gene sets for estimating ER pathway activity in
breast tumors. A combination of bioinformatic inference of ER
pathway activation using these gene sets, together with information
regarding ER-a IHC and ESR1 mRNA expression, might provide a
broad-based assessment of breast tumor ER status.
It is interesting that these 2 gene sets and other gene sets previ-
ously associated with the estrogen response shared little overlap with
one other (Supplemental Figure 4; available in the online version).
Presumably this resulted in part from the differing intentions when
each of these gene sets was generated (Supplemental Table 3;
available in the online version). For example, some of these sets
consist of genes summarizing biological pathway activation, which
might identify the intactness of the signaling pathway components.
Other sets are composed predominantly of genes expressed as a
downstream consequence of estrogen signaling and might therefore
act as biomarkers for ER activity. Finally, some gene sets were
originally designed to be clinically prognostic or predictive. The lack
of concordance between ER-associated gene sets does not appear to
be solely due to differing levels of statistical stringency. For example,
a revised analysis of the mRNAs differentially expressed in MCF7
cells after siRNA targeting of ESR1 using a much less stringently
adjusted P value cutoff of P  .05 did not change the intersection
with the small Endopredict gene set (12%; data not shown). For
other gene sets, such as the large gene set from Oh et al,53 relaxing
our adjusted P value cutoff to P  .05 actually reduced the inter-
section (from 28% to 20%; data not shown). The disparity of the
prognostic and predictive gene lists can also be attributed to
numerous factors, such as heterogeneity in the patient populations
used, the use of different microarray platforms coupled with
different probe sets, and different methods of data normalization
and sampling variation. Furthermore, this observation could have
resulted from the heterogeneity of tumor tissue, in which ESR1-
regulated genes are only a small part of the greater part of the breast
tumor transcriptome, or the in vitro response of relatively homog-
enous cultured cell lines might not reproduce estrogen signaling
in vivo. Despite their differences, these multiple gene sets mightpossibly be effective in summarizing different aspects of estrogen
pathway activity. At present, IHC hormonal status remains an
invaluable tool for breast cancer diagnosis, prognosis, and prediction
to endocrine treatment response. This is partly because no reference
standard method is available to compare all the different mRNA
biomarkers or signatures of estrogen signaling in breast cancer cells.
Furthermore, each signature of estrogen activity or signaling that has
been identiﬁed was designed to capture slightly different aspects of
estrogen signaling, rendering it difﬁcult to directly compare and
contrast each signature with each other. Our proposed multimodal
approach of using IHC ER status, ESR1 mRNA abundance, and a
genomic indicator of estrogen pathway activity negates the need to
compare 1 type of measurement against another. Prospective clinical
studies with larger patient numbers and survival data would provide
more information on how these 3 parameters could be used better
or weighted, for example, to stratify patients for treatment, and
further reﬁnements could be made to improve our multimodal
approach by including other relevant molecular or clinical data.
With large patient numbers and patient follow-up data, our signa-
tures, along with other published estrogen signatures, could be
compared more robustly.
Despite their differences, most of the ER-associated gene sets we
studied appeared to have prognostic power. Five estrogen-associated
gene sets in particular (MCF7-ESR1-siRNA ﬁrst PC, genes differ-
entially expressed between ERþ and ER tumors, Endopredict,55
PAM50,62 and the simpliﬁed tamoxifen predictor56) had espe-
cially strong prognostic associations across our multicohort data set
for patients receiving endocrine therapy, although not for untreated
patients (Figure 6), suggesting that they might capture clinically
valuable information regarding endocrine treatment response
pathways. In addition, the PCs from the MCF7-ESR1-siRNA ﬁrst
PC, the simpliﬁed tamoxifen predictor, PAM50, and the Endo-
predict gene set appeared to add prognostic information to logistic
regression analysis over and above the ER IHC status or ESR1
mRNA levels. The abundance of ESR1 mRNA itself had relatively
weak associations with patient outcomes in our tumor data set. In
future studies, it will be interesting to assess the statistical in-
teractions in prognostic models between ER-associated gene sets and
intrinsic subtype, proliferative variables, and other clinicopathologic
features.
Breast Tumor Heterogeneity and Utility of Genomic
Estimates of ER-a Pathway Activity
Intratumor heterogeneity is a feature of some breast tumors and
their metastases,79 in terms of their cell biology, gene expression,
ERBB2 status, and IHC ER status.80 IHC has a clear advantage over
microarray or RT-qPCR analysis for the detection of the ER-a
protein in small regions of heterogeneous tumors that might later
become clinically important. The proportion of tumor cells to stromal
cells in breast tumors varies immensely, and IHC techniques can
allow the determination of the percentage of tumor cells in a given
section that is assessed. Similarly, the intensity and distribution
pattern of the ER-a protein within an already heterogeneous tumor
can be accurately detected. In contrast, using mRNA to proﬁle tu-
mors has a limitation, because the heterogeneity in mRNA expression
within the cells and the tumor cell versus stromal cell composition
within the section is combined and the resulting expression signalsClinical Breast Cancer Month 2016 - 11
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12 -averaged. However, it was shown that despite their heterogeneity, the
variation between tumors was greater than the variation within tu-
mors.81 Furthermore, in addition to inaccuracies in hormone receptor
status assignment, possibly due to variations, IHC provides no in-
formation regarding the functional status of the ER-a protein or the
ER signaling pathway. Multiple other potential mechanisms might
also account for the apparent dislocation between ER-a IHC and ER-
driven transcriptional responses, such as the action of ER-b and the
androgen receptor, and suppression of ER protein cell surface
expression despite mRNA expression. Finally, the relationship be-
tween the frequency and intensity of ER positivity in tumor cells and
treatment response remains unclear. Although some studies have
suggested that patients beneﬁted from endocrine therapy, even if as
few as 1% of their tumor cells exhibited moderate to strong ER-a
protein staining,15 a recent retrospective study of 9639 patients found
that patients with tumors with 1% to 9% staining of ER-a did not
appear to beneﬁt as much from endocrine therapy compared with
those with  10% staining.82 Furthermore, it was also shown that
patients with 1% to 9% ER positivity using IHC exhibit a molecular
proﬁle similar to that of patients with ER tumors, and a high
proportion of these tumors are of the basal-like molecular sub-
type.14,83 These investigators suggested that the assignment of ER
positivity in these tumors might not reﬂect the biology of the tumors
and that these patients might not beneﬁt from endocrine therapy.83 A
variant of ER-a called ERD7 might function in a dominant negative
manner and is highly expressed in ERþ basal tumors.11 Another
study identiﬁed tumors with 1% to 9% ER positivity by IHC
behaving similar to ER tumors using RT-qPCR and reported that
the survival of patients in this subset of 1% to 9% positivity were
intermediate, between that of the remaining ERþ (>10% positivity)
and ER tumors.84
It has also been argued that with the increased sensitivity of ER
antibodies such as SP1 and, hence, the increased bimodal distri-
bution of ER status (90% ERþ), perhaps the range of ER expression
is no longer relevant because all suitable patients with > 1% ER
positivity will be prescribed endocrine therapy.16 However, if the
assignment of ER status is critical to determine patient response to
endocrine therapy and the threshold for ER positivity is > 1%
positive staining, it is imperative that the rate of false-negative re-
sults during ER status determination using IHC be dramatically
reduced.16 The effect of the established guidelines regarding ER
status testing in breast cancer is currently under investigation.
However, the effect of these guidelines around ERBB2 status testing
in breast cancer has been reviewed. The ﬁndings have revealed an
overall increase in the ERBB2 positivity rate.85 Also, a greater
proportion of tumors were reassigned to an equivocal ERBB2 status
from an ERBB2 status, which enabled these patients to receive
trastuzumab and potentially beneﬁt from this treatment.86 Thus, it
is important to interpret with caution any ﬁndings generated from
publicly available microarray data sets, because an expectation
would exist that a proportion of the tumors would have inaccurate
hormone receptor status.
An argument also exists that the bimodal distribution of ER status
is not an accurate representation of the true biologic continuum of
ER expression.5,87 It has been reported that tumors with low levels of
ER expression (<10% positivity) are difﬁcult to classify,88,89 with
considerable interlaboratory variation for low ER positivity with aClinical Breast Cancer Month 2016false-negative rate of 30% to 60%.88 Also, a slightly greater discor-
dance was found in tumors with low ER positivity (1%-10% stain-
ing) when 2 different ER antibodies and 2 different scoring methods
were used.89 Hence, the determination of ER status, in particular, for
tumors with low ER positivity becomes important when stratifying
for treatment, especially because the potential beneﬁts of endocrine
therapy for this subset of patients are still unclear.
Owing to the heterogeneity and complexity of breast cancer, an
integrated and multisystems approach is likely the best method to
model this disease, because no single model is likely to recapitulate
all aspects of this disease.90-92 PC analysis in multimodal approaches
is valuable when integrating in vitro and in vivo gene expression
signatures in breast cancer.93,94 However, no method has been
recommended to integrate in vitro and in vivo data or to integrate
clinicopathologic information from conventional tests with
molecular-based studies, although a general consensus has been
reached that combining both types of information to improve the
management of breast cancer, rather than relying on 1 method
alone, or advocating the use of prognostic gene expression proﬁles
instead of clinicopathologic prognostic indicators is better.
In our data set, several tumors were IHC ERþ despite expressing
low levels of both ESR1 mRNA and ER-induced genes. These
might represent tumors that would beneﬁt from endocrine-based
therapy to target ERþ regions of their heterogeneous areas, such
as is current clinical practice. However, we also noted 21 tumors
that were IHC ER despite apparently having active ER tran-
scriptional pathways, indicated by high levels of both ESR1 mRNA
(ESR1 probe set cutoff,  6.25; see Materials and Methods) and ER
molecular pathway activity (PC cutoff,  0.01; see Materials and
Methods; Figure 7A, black dots). These potentially represent a
previously hidden set of patients who have IHC ER tumors
(hidden possibly because of technical rather than biologic reasons)
but might nevertheless beneﬁt from endocrine-based treatment. The
presence of ER-a in tumors has been shown to be associated with a
good prognosis in patients and also suggests the likelihood of a
response to endocrine therapy in ERþ patients. We suggest that this
patient group requires further study. The next sensible step might
be to conduct a prospective clinical study with larger numbers of
patients and to assess the metastasis-free survival of noneendocrine-
treated IHC ER patients to determine whether noneendocrine-
treated IHC ER patients with high ESR1 mRNA expression and/
or high estrogen pathway activity PC have better survival outcomes
than noneendocrine-treated IHC ER patients with lower ESR1
mRNA expression and/or low estrogen pathway activity PC. Simi-
larly, the metastasis-free survival of any ERþ patients who were not
prescribed endocrine therapy could be followed up and assessed to
determine whether noneendocrine-treated ERþ patients with high
ESR1 mRNA expression and/or high estrogen pathway activity PC
have better survival outcomes than noneendocrine-treated IHC
ERþ patients with lower ESR1 mRNA expression and/or low es-
trogen pathway activity PC. However, in applying our proposed
multimodal method to an ERþ cohort clinically requires a more
careful approach, because it has been shown that patients who are
ERþ have a very good prognosis and those who undergo endocrine
therapy beneﬁt from the treatment. Nevertheless, the ERþ cohort in
this context would be clinically useful for investigating the devel-
opment of endocrine resistance and/or relapse in these patients.
Anita Muthukaruppan et alPGR status has been indicative of an intact ER-a signaling
pathway in ERþ patients. However, extrapolating the intactness of
the ER-a signaling pathway using IHC PGR alone results in the
process of PGR status assignment having the same discrepancies
associated with the IHC technique, as discussed previously. The
distribution of PGRþ and PGR patients (n ¼ 639) was similar to
the distribution of ERþ and ER patients (n ¼ 1034) when the
magnitude of our PC of estrogen pathway activity was plotted
against ESR1 mRNA expression (Figure 4F and 5A, respectively).
However, similar to our observation of IHC ER patients, a pro-
portion of IHC PGR patients had high ESR1 mRNA expression
and high estrogen pathway activity PC. However, some IHC PGR
patients also had low PGR mRNA expression but varying magni-
tudes of estrogen pathway activity PC. It might be possible that
some of these IHC PGR patients were IHC ERþ; hence, these
patients might have been prescribed endocrine therapy. The exis-
tence of ER/PGRþ tumors has been questioned, investigated, and
conﬁrmed.95-98 Itoh et al75 suggested the use of ESR1 mRNA
expression to help stratify ER/PGRþ patients, and approximately
25% of these patients’ tumors had the molecular proﬁle of ERþ
tumors with similar relapse-free survival to that of ERþ/PGRþ
patients.75 Shen et al99 also showed that patients who were ER/
PGRþ had a relapse-free survival similar to that of ERþ/PGRþ
patients and had a better response to endocrine therapy than ERþ/
PGR patients. Multimodal assessments of tumors using a PC of
estrogen signaling and ESR1 and/or PGR mRNA expression,
together with IHC ER/PGR status, would be extremely useful in
stratifying breast cancer patients for endocrine treatment. Schroth
et al97 showed that in ER/PGRþ patients, 59 unique mRNAs were
differentially regulated, including ESR1 and GATA3.97 It is
reasonable to assume that PGR status and ER status both correlate
with our PC of estrogen pathway activity across our breast tumors.
However, further patient stratiﬁcation is required to investigate
these multiple parameters robustly.
It would also be useful to investigate further other clinical aspects
of the patients in our data set, such as type of endocrine received
(tamoxifen vs. aromatase inhibitors), menopausal status (pre- and
postmenopausal), and time to relapse in regard to IHC ER status,
ESR1 mRNA abundance, and PC of estrogen signaling. However,
the clinical data for the analyzed data sets did not possess this level
of detail for us to investigate these factors robustly in our study. In
the present study, we built on this work by illustrating the potential
complementarity of determining ER status using ESR1 mRNA
expression, gene set-based biomarkers for ER pathway activation,
and ER IHC in a large and well-annotated data set. We suggest this
might be especially helpful to identify patients with IHC ER tu-
mors that nevertheless express high levels of both ESR1 mRNA and
ER-induced genes. We also suggest that, according to the analyses of
multiple ER-associated gene sets (Supplemental Table 3; available in
the online version), the information added to ER-a IHC and ESR1
expression by RT-qPCR measurements of single genes such as
CA12, NPY1R, STC2, DKC1, and PGR is investigated.
Conclusion
Several gene sets representing ER activity have been previously
identiﬁed. However, the transcriptional consequences of ER
pathway signaling and the biologic meaning of ER gene expressionsignatures for the prognosis and prediction of endocrine therapy
response are still incompletely understood. In addition, previously
published gene sets proposed to reﬂect ER signaling are highly
divergent. In the present study, we have shown that despite their
differences, most previously published ER-associated gene sets and
the 2 new gene sets reported in the present study, have statistically
signiﬁcant associations with patient outcome. The principal com-
ponents of ER-associated gene lists, or individual highly ER-
responsive genes, appear to provide valid indicators of ER
pathway activity. We propose that combining the statistical sum-
maries of ER-driven gene sets with ER-a IHC and ESR1 mRNA
expression can provide the most robust indicator of ER signaling in
the breast tumors of individual patients for research and clinical use.
Clinical Practice Points
 We propose that a 3-way assessment of breast tumor ER biology,
combining ER status, ESR1 mRNA expression, and inferred ER
pathway activity using PC analysis, could in the future increase
the robustness of ER pathway activity estimates in research and
when stratifying patients for endocrine-based therapy.
 We suggest that a “hidden” set of patients might exist who have
ER tumors by IHC but also have active ER transcriptional
pathways (indicated by high levels of both ESR1 mRNA and ER-
induced genes) and thus might potentially beneﬁt from
endocrine-based therapy.Acknowledgments
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